An expert panel gathered by the FDA has endorsed GlaxoSmithKline's new kidney cancer therapy, pazopanib. The group voted unanimously that the...
Companies in the Buzz
Recommended Sources
Recommended Publications
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.
Web Buzz:
-
FDA Panel Backs Glaxo?s Votrient
Seeking Alpha - 157 days 12 hours 51 minutes ago
Links from the Web Buzz:
- Merck's Troubled Cholesterol Drug Vytorin Awaits Rescue -- Three Years Too Late
- Sequenom's Disappearing Down Syndrome Test Mystery -- Solved!
- Merck is Shocked -- Shocked! -- to Discover That Some Drug Ads Are "Deceptive"
- Now He's a Cartoon: Microchip Implant CEO's PR Troubles Go From Bad to Worse
- Feds Probing Pfizer's Kidney Drug May Want to Check a Certain Pharma Gossip Site ...
- Facet Biotech Has $722M That Says It Pays to Stand Up to Bullies
- FDA Issues Rare Quadruple Warning to Kidney Drug Maker; Next Up, Double-Secret Probation
- At Novartis, It's Pregnant Women vs. Cheerleaders Among the Sales Reps
- Drugs on Twitter: Big Pharma Lobbies for New Rules in Social Media
- Trial Spotlights Pentagon Use of Unapproved Antipsychotics for Post-Traumatic Stress
- The Hidden Autism Agenda Behind the Vaccine Case Headed for the Supreme Court
- Missing Data? Feh. In Sequenom's Hall of Mirrors, Investors See Only What They Want
- Big Biotech M&A Targets: Who Could Follow Astellas' $3.5B Bid for OSI?
- Novartis and Vanda Pharma's Schizophrenia Treatment May Be DOA
- Sanofi, European Regulators to Bald Breast-Cancer Patients: Drop Dead
- New York Bills Would Mandate HPV Vaccines Without Parents' Consent
- Acne Drug Accutane's Side Effect Is Death. So Why Is It Still on the Market?
- Why You Should Ignore Jim Carrey and Jenny McCarthy's Autism Delusions
- Acorda Therapeutic's MS Drug Ampyra Could Stumble
- Crazy Question: What If Sequenom's Down Syndrome Test Doesn't Exist?
- If Approved -- FDA Drug Labeling Could Decide Ultimate Success of MannKind's Afrezza
- Conspiracy Theory About Dendreon's New Cancer Drug Could Soon Unravel
- Roche's Accutane: Suit Over Death of Congressman's Son Nixed
- Efficacy of Roche's Flu Drug Tamiflu In Doubt
- If Approved -- FDA Drug Labeling Could Decide Ultimate Success of MannKind's Afrezza
- Why J&J's Stelara Launch Should Target Dermatologists First
- 2010 FDA Approvals Could Lead to Launch of Eight Blockbuster Biotech Drugs
- The 5 Worst Drug Companies of 2009
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- Abbott Labs' Deal with Teva Pharma Is 'Phat News' for Lipid-Lowering Franchise
- How Much To Extend Life? Allos Therapeutics Says $30,000 per Month
Industry Transcripts by Seeking Alpha
- XOMA Ltd. Q4 2009 Earnings Call Transcript
- Peregrine Pharmaceuticals, Inc. F3Q10 (Qtr End 01/31/10) Earnings Call Transcript
- Mannatech, Incorporated Q4 2009 Earnings Call Transcript
- Chelsea Therapeutics International, Ltd. Q4 2009 Earnings Call Transcript
- Emergent BioSolutions Inc. Q4 2009 Earnings Call Transcript
Brought to you by CBS MoneyWatch.com
- Best- and Worst-Paid College Degrees
- 6 Things You Should Never Do on Twitter or Facebook
- How Much Sleep Do You Really Need?
- 6 Big Myths about Gas Mileage
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
BNET User Analysis